Kiniksa(US:KNSA) ZACKS·2025-10-28 13:40Core Insights - Kiniksa Pharmaceuticals International, plc reported quarterly earnings of $0.23 per share, missing the Zacks Consensus Estimate of $0.33 per share, representing an earnings surprise of -30.30% [1] - The company posted revenues of $180.86 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 8.91% and showing a year-over-year increase from $112.21 million [2] - The stock has gained approximately 105.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 16.9% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.42 on revenues of $175.84 million, and for the current fiscal year, it is $1.05 on revenues of $636.48 million [7] - The estimate revisions trend for Kiniksa Pharmaceuticals was favorable prior to the earnings release, resulting in a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Kiniksa belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook for stocks within this sector [8] - Another company in the same industry, XOMA Royalty, is expected to report a quarterly loss of $0.02 per share, reflecting a year-over-year change of +94.9%, with revenues anticipated to be $12.59 million, up 74.8% from the previous year [9]